New name, but same old problems for Posimir as FDA hits Durect again

Ben Adams Durect may have changed the name of its post-pain gall bladder surgery drug from "Posidur" to "Posimir" this year, but this has not stopped its run of ...

UPDATED: OncoMed hits the brakes on PhII pancreatic cancer trial, shares plummet

John Carroll OncoMed slammed the brakes on a Phase II study of the cancer stem cell drug tarextumab, citing worsening response rates in the drug arm for pancreatic cancer, with red ...

Amgen hits a snag in its plot to challenge AbbVie’s blockbuster Humira

Damian Garde Amgen, at work on a biosimilar of AbbVie's best-selling treatment, got an unfavorable decision from U.S. regulators that could delay the launch of its take on Humira. FierceBiotech ...

Anthera hits another setback as its Japanese partner quits on blisibimod

Damian Garde Anthera Pharmaceuticals is back on the hunt for a partner in Asia after Japanese drugmaker Zenyaku pulled the plug on the pair's collaboration, clouding the future ...

Avalanche hits the brakes on its gene therapy program after a Phase II misstep

Damian Garde Avalanche Biotechnologies, months removed from a costly Phase II dud, is calling off plans for further study of its lead gene therapy candidate, heading back to the lab ...

Genocea’s herpes vaccine hits the mark in Phase II

Damian Garde Genocea Biosciences' in-development vaccine for genital herpes met its goals in a Phase II trial, sending the biotech's shares soaring. FierceBiotech News

Auspex’s Huntington’s drug hits the mark in Phase III

Damian Garde Auspex Pharmaceuticals' treatment for a movement disorder tied to Huntington's disease met its main goal in a late-stage study, the company said, clearing the way ...

Karolinska Development’s CEO leaves, Erytech hits PhIII endpoints, VBL belatedly nails IPO

Nick Paul Taylor Welcome to the latest edition of our weekly EuroBiotech Report. FierceBiotech News

Sanofi hits Lilly with more Lantus infringement charges

Carly Helfand Sanofi has already slapped Eli Lilly with one patent infringement lawsuit over its Lantus copy, effectively keeping the competitor off the market until ...

Alzheimer’s R&D suffers as trial failure rate hits an ‘astounding’ 99.6%

John Carroll Jeffrey Cummings is directing one of the few early-stage studies underway on an Alzheimer's therapy. And now that he's scanned the records of clinicaltrials.gov, ...

GW hits the FDA fast track with its cannabis-based epilepsy drug

Damian Garde The FDA has applied its fast-track designation to GW Pharmaceuticals' Epidiolex, a cannabinoid treatment for a rare form of epilepsy. FierceBiotech News

Alkermes hits key milestone on pivotal PhIII schizophrenia study

John Carroll Ireland's Alkermes has hit a key milestone in its quest to develop a long-acting version of Abilify for schizophrenia. The biotech, which has R&D operations in ...
Page 1 of 3123
© 2017 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS